Cargando…
Insulin degludec aspart: One-year real world experience
BACKGROUND: This retrospective analysis describes the use of insulin degludec aspart (IDegAsp) in India. MATERIAL AND METHODS: All subjects who had received IDegAsp for 52 weeks at two endocrine centers were included in this study. RESULTS: Forty-eight subjects (40 men), with mean age of 54.33 ± 9.6...
Autores principales: | Kalra, Sanjay, Baruah, Manash P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855967/ https://www.ncbi.nlm.nih.gov/pubmed/27186556 http://dx.doi.org/10.4103/2230-8210.177416 |
Ejemplares similares
-
Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016) -
Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011) -
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014) -
Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience
por: Oner, Hatice, et al.
Publicado: (2022) -
Abstract 28: Change in glycaemic parameters in adults with type 2 diabetes initiated with or switched to insulin degludec/insulin aspart (IDegAsp) in a real-world setting – An analysis of Indian cohort of ARISE study
por: Baruah, Manash P, et al.
Publicado: (2022)